Third Rock Ventures has led a series A round for Abata Therapeutics, launched by the firm to commercialise research from Harvard, MIT, Johns Hopkins, NIH and UZH.

Harvard-aligned venture capital firm Xfund has reinvested in ImmuneID, which is developing precision immunology therapies based on Harvard University and Johns Hopkins University research.

MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

The Cornell cardiovascular data technology spinout has launched with $54m in funding, $43m coming from an American College of Cardiology-backed series B round.

Nutreco and Olympic Investments co-led a $49.8m round for the mycoprotein ingredient developer and University of Strathclyde spinout that included Axa.

The oncology therapeutics developer has added $66m to its coffers thanks to investors including Berkeley Catalyst Fund.

Alexandria Venture Investments was among the participants in a series A for the cellular cancer therapeutics developer based on work at Institut Curie and Memorial Sloan Kettering.

Morningside Venture Investments has led a series B round for the fibrotic diseases-focused spinout that advances University of Strasbourg research.

The Tsinghua-backed DNA and RNA sequencing equipment manufacturer has added $63m to its coffers.